What is it about?
For the short-term treatment of proliferative lupus nephritis, current evidence is insufficient to determine the superiority of any of the immunosuppressive therapies.
Featured Image
Why is it important?
Immunosuppressive therapies may be equivalent in the initial treatment at 6 months of proliferative lupus nephritis.
Perspectives
Based on trial evidence for adult patients with proliferative lupus nephritis, immunosuppressive therapies were shown to be equivalent for the first 6 months of treatment.
Mr Simon Y. Tian
University of Toronto
Read the Original
This page is a summary of: Immunosuppressive Therapies for the Induction Treatment of Proliferative Lupus Nephritis: A Systematic Review and Network Metaanalysis, The Journal of Rheumatology, September 2014, The Journal of Rheumatology,
DOI: 10.3899/jrheum.140050.
You can read the full text:
Contributors
The following have contributed to this page
